DAI-NIPPON-PRINTING
Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) has developed a Reflect Array that flexibly reflects the millimetre waves used in fifth generation (5G) mobile communications systems to expand coverage area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005245/en/
Compared to general metal reflectors, the new product is capable of reflecting millimetre waves in a more targeted manner. As a result, there are fewer restrictions on installation, making it possible to improve the communications environment in locations where radio waves have been difficult to reach, such as those in the shadow of buildings. In addition, the new product boasts superior design features allowing it to respond to various installation environment considerations.
Background
The 24GHz and above radio waves used in the high-speed large-capacity communications of 5G are higher frequency milliwaves than those used in 4G, and maintain a larger information capacity. At the same time, they are characterized by strong straightness properties and short reach, leading to radio waves being blocked in areas such as in the shadow of buildings making it difficult to ensure communication quality. Also, when adding base stations and relay equipment to resolve this issue, new challenges emerge, such as large costs and the difficulty of securing installation space.
DNP has once again risen to the challenge, taken advantage of proprietary microfabrication technology, and by applying an original concept has successfully separated the Frequency Selection Reflection Layer that selectively reflects predetermined frequency bands while merely passing through other radio waves, and the Reflective Direction Control Layer, a special dielectric layer that decides the direction of incoming and reflected radio waves, to develop a Reflect Array that makes it easier to control for the characteristics of each layer. The newly developed product is cheaper than installing base stations and relay equipment, and does not require a power source. It can, therefore, be installed in a variety of location, which contributes to significant improvements in the 5G communications environment.
Features
- Can be installed in a variety of locations
Unlike metal reflectors that reflect radio waves directly as in a mirror, the newly developed product is a reflective array capable of the asymmetric reflection of specific frequency radio waves. It is possible to flexibly set the frequency band to be reflected, the incidence angle of the radio waves received from the base station, and the reflection angle to deliver the radio waves, along with the spread of the reflection waves. As a result, it is now possible to effectively deliver radio waves to locations where it was previously difficult to do so. As a power source is no longer needed the new product can also be used in locations where installation space is restricted.
- Effective designs based on original concepts
The new product is comprised of three layers: the Frequency Selective Surface Layer that selectively reflects predetermined frequency bands while merely passing through other radio waves, the Reflective Direction Control Layer that decides the direction of incoming and reflected radio waves, and a Design Cover Layer that not only protects these two layers, but also provides the durability required of construction materials along with high level design features that are conducive to various installation environment considerations.
- Effective improvement of radio wave conditions
We have made it is possible to pre-adjust the spread of the reflection waves in answer to the desire to deliver reflection waves over a broad area, or to gather those waves into specific devices.
- Reduces the impact on existing radio waves
Unlike metal reflectors that reflect all radio waves, the new product passes through all but target radio waves, reducing the impact on existing radio waves.
- Superior design features
It is possible to print various patterns on the surface of the Design Cover Layer, making it possible to add external designs, including interior, exterior and advertising signboards.
Usage Scene
Recently, we have seen more companies and organizations consider the adoption of 5G as a means of targeting the realization of smart cities and smart factories that exploit robots and the Internet of Things (IoT). Commercialization efforts are already underway. With the development of the Reflect Array, we anticipate the following installation instances in cases where the radio wave environment is expected to deteriorate due to obstacles, and aim to link these initiatives to the spread of 5G.
- Improvement of the communication environment behind radio wave shields in smart factories
- Improvement of mobile device usage environment indoors at business offices and educational sites
- Usage at exhibition spaces where layouts change with each event and radio wave shielding conditions alter
- Usage at stadiums and amusement facilities where area-specific information is delivered
- Applications leveraging design elements, such as urban buildings, walls and signboards that require harmony with the surrounding environment
Looking Ahead
DNP will work jointly with various communications-related companies, including communications carriers, to verify the functionality of the new product, aiming for commercialization from FY 2023.
The new product is a Passive type Reflect Array that fixes the reflection direction of the radio waves. We will engage in joint development of an Active type Reflect Array with multiple companies, and this research has been selected as a national project in FY2021.
About DNP
DNP is one of the world’s largest comprehensive printing companies, providing a diverse portfolio of products and services to about 20,000 corporate clients worldwide. Since we were founded in 1876, we have consistently innovated new products and processes, and have successfully integrated proprietary printing and information technologies to branch out into various fields, including packaging, decorative materials, display components, and electronic devices. DNP continues to take on the challenge of new business fields, including those related to the environment, energy, and life sciences. Our aim is to become a principal provider of solutions to a variety of problems by developing and combining new technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005245/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
